Antiphospholipid antibodies and pregnancy

Best Practice & Research. Clinical Haematology
Monica Galli, Tiziano Barbui

Abstract

Antiphospholipid antibodies, i.e. lupus anticoagulants and anticardiolipin antibodies, are associated with obstetric complications. Fetal death and recurrent spontaneous abortions represent the obstetric criteria of the antiphospholipid syndrome. They occur with similar frequences and have an overall prevalence of 15-20%. Lupus anticoagulants carry a risk 3.0 to 4.8 times, and anticardiolipin antibodies 0.86 to 20 times higher than controls. The mechanism(s) by which antiphospholipid antibodies cause these events still has to be defined: thrombosis in the placental vessels, and impairment of embryonic implantation have been proposed. Unfractionated or low-molecular-weight heparin, alone or in combination with low-dose aspirin, represent the current standard treatment of pregnant antiphospholipid-positive women for preventing recurrent obstetric complications. Upon treatment, the live birth rate increases from 0-40% to 70-80%. However, there is still an excessive frequency of maternal and/or fetal complications, indicating the necessity of a better calibration of the dosage, duration and timing of administration of heparin treatment.

References

Jan 1, 1991·Journal of Clinical Pathology·M D CreaghM Greaves
Oct 10, 1991·The New England Journal of Medicine·C Infante-RivardG E Rivard
Oct 8, 1991·European Journal of Obstetrics, Gynecology, and Reproductive Biology·H J OutR H Derksen
Apr 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·M BlankY Shoenfeld
Jun 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·H P McNeilS A Krilis
Feb 1, 1989·American Journal of Obstetrics and Gynecology·M D LockshinT Qamar
Jun 1, 1996·British Journal of Haematology·M Frezzato, F Rodeghiero
Oct 5, 1996·Lancet·F E PrestonF J van der Meer
Sep 1, 1996·Leukemia & Lymphoma·M GriesshammerT C Pearson
Jul 17, 1997·The New England Journal of Medicine·C A LaskinM Yeung
Sep 12, 1998·British Journal of Haematology·P GiordanoD de Mattia
Nov 14, 1998·Lupus·M D Lockshin
Dec 3, 1999·Human Reproduction Update·S DayaD A Clark
Feb 24, 2000·Fertility and Sterility·M D HornsteinJ A Collins
Jan 5, 2002·Obstetrics and Gynecology·Marianne EmpsonJames R Scott

❮ Previous
Next ❯

Citations

Mar 28, 2007·La Presse médicale·Jean-Louis PasqualiThierry Martin
Sep 18, 2012·International Journal of Laboratory Hematology·G W MooreM R Ledford-Kraemer
Dec 4, 2010·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·A SucakG T Sucak
Aug 17, 2005·Journal of Thrombosis and Haemostasis : JTH·I Pabinger, R Vormittag
Apr 1, 2015·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Akanksha RawatKiran Guleria
Sep 17, 2009·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·S P SahaB K Goswami
Mar 19, 2005·Human Reproduction·Henriette Svarre Nielsen, Ole Bjarne Christiansen
Nov 12, 2014·Postgraduate Medicine·Ariela L Marshall
Nov 4, 2004·European Journal of Haematology·V BladtF d'Amore

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.